Skip to content

New Orleans Pulmonary Hypertension Biobank

New Orleans Pulmonary Hypertension Biobank

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03269630
Acronym
NO-PH Biobank
Enrollment
450
Registered
2017-09-01
Start date
2017-12-29
Completion date
2027-10-31
Last updated
2021-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Heart Failure With Normal Ejection Fraction, Mixed Connective Tissue Disease, Pulmonary Hypertension, Systemic Sclerosis

Brief summary

Pulmonary hypertension (PH) is a serious condition characterized by a mean pulmonary artery pressure \>=25mmHg on right heart catheterization (RHC). Despite advances in PH care, outcomes are still sub-optimal and further research is required into the pathobiology of the disease and development of biomarkers that can guide clinical care. The investigators are establishing a biobank to collect samples (blood, urine, stool) from patients with pulmonary hypertension, patients at high risk for pulmonary hypertension, healthy controls, and patients undergoing right heart catheterization. Specimens will be stored for future investigations.

Interventions

OTHERNo intervention. Biospecimen collection only

Biospecimen collection

Sponsors

Louisiana State University Health Sciences Center in New Orleans
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of pulmonary hypertension and followed at the Comprehensive Pulmonary Hypertension Center OR * Diagnosis of systemic sclerosis and followed at the Comprehensive Pulmonary Hypertension Center OR * Diagnosis of mixed connective tissue disease and followed at the Comprehensive Pulmonary Hypertension Center OR * Undergoing outpatient right heart catheterization

Exclusion criteria

* Age\<18 * Pregnant * Unable to understand English * Currently incarcerated * Unwilling or unable to sign informed consent

Design outcomes

Primary

MeasureTime frameDescription
Collection of biospecimens10 yearsBiospecimen collection only

Countries

United States

Contacts

Primary ContactMatthew R Lammi, MD, MSCR
mlammi@lsuhsc.edu5045684634

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026